Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.4 - immediate hazard: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 4: | Line 4: | ||
|RefDocPart=4.4 - immediate hazard | |RefDocPart=4.4 - immediate hazard | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00246-Inv-hte ++ TAG-00017-Spo-die ++ TAG-00069-Imm-rhe ++ TAG-00041-Ame-run ++ TAG-00329-Saf-lne | ||
| | |RefModule=5 | ||
| | |RefUnit=5.4.1 | ||
}} | }} | ||
| Line 14: | Line 14: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 5 — Unit 5.4.1 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 30: | Line 33: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00246-Inv-hte|Investigator responsibilities]], [[Glossary:TAG-00017-Spo-die|Sponsor]], [[Glossary:TAG-00069-Imm-rhe|Urgent safety measure]], [[Glossary:TAG-00041-Ame-run|Amendment]], [[Glossary:TAG-00329-Saf-lne|Safety]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | WHO WHO - Guidelines for GCP for trials on
pharmaceutical products* 1995 |
| Validity area | WHO |
| Scope(s) | HM |
| Document name | WHO - Guidelines for GCP for trials on
pharmaceutical products* |
| Version / Revision | 1995 |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | World Health Organization
WHO Technical Report Series, No. 850, 1995, Annex 3 Guidelines for good clinical practice (GCP) for trials on pharmaceutical products* |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 — Unit 5.4.1 |
| Scope | HM |
| Document part | 4.4 - immediate hazard |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Investigator responsibilities, Sponsor, Urgent safety measure, Amendment, Safety |
| Comment | Investigator changes to study require sponsor agreement |
Content
[...] The investigator should not make any changes in the study without the agreement of the sponsor, except when necessary to eliminate an apparent immediate hazard or danger to a trial subject. [...] The investigator may take any steps judged necessary to protect the safety of the trial subject, whether specified in the protocol or not. Any such steps must be documented.
